Shopping Cart
Remove All
Your shopping cart is currently empty
Akt1-IN-8 (Compound JL18) is a potent AKT1 kinase inhibitor with oral bioavailability of 41% and an IC50 value of 8.8 nM. It exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC50 of 3.0 μM. Akt1-IN-8 also reduces phosphorylated GSK3β levels.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Akt1-IN-8 (Compound JL18) is a potent AKT1 kinase inhibitor with oral bioavailability of 41% and an IC50 value of 8.8 nM. It exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC50 of 3.0 μM. Akt1-IN-8 also reduces phosphorylated GSK3β levels. |
| Targets&IC50 | Akt1:8.8 nM |
| Molecular Weight | 551.278 |
| Formula | C21H25Br2N7O |
| Cas No. | 2247688-87-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.